DUBLIN–(BUSINESS WIRE)–The “Global
Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity
Insight 2026” report has been added to ResearchAndMarkets.com’s
offering.
“Global Cell Therapy Market, Clinical Trials, Therapy Price &
Opportunity Insight 2026” Report Highlights
-
Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by
2026 - Cell Therapy Clinical Trial Insight by Indication, Company & Country
- Global Cell Therapy Clinical Pipeline: 767 Cell Therapies
- Globally Marketed Cell Therapies: 25 Cell Therapies
- Maximum Number of Marketed Cell Therapies In USA: 15 Therapies
- Price & Product Insight By Region/Country
- Regional Analysis of the Cell Therapy Market
In recent years, there has been a steady increase in the interest shown
in the cell therapy segment from big pharmaceutical, biotech and medical
device companies. Earlier, the idea for altering a cell or a gene to
cure or treat disease was considered impossible. But with the ongoing
advancements, it has now become possible in the treatment or cure of a
disease with the help of cell therapy.
Cell therapies are still in the early stages of clinical development and
are expected to evolve in the market with a vast number of opportunities
in the healthcare industry. In order to form a stable base for process
evaluation and development it will be essential to understand the
quality of cell-based products. With an increasing number of cell
therapies and clinical indications being assessed, it is clear that
consideration will be given on how these therapies will be carried out
and subsequently be delivered to the patients on a clinical relevancy
scale.
Currently, there are more than 750 cell-based therapies in the clinical
pipeline. Most of the cell therapies are in Preclinical phase followed
by Phase-I clinical trials. Analysis of the pipeline shows that the
majority of the cell therapy products that are currently under
development are targeted towards treatment of complex disease like
cardiovascular disease, neural disease and cancer. More than 20 cell
therapies are commercially available in the market. However, when it
comes to marketed products, more than half of the products that are
currently available are in the tissue and skin treatment segment such as
Apligraf and Dermigraf.
Few cell therapy products such as Kymriah, Provenge and Yescarta have
emerged as the most promising therapeutics of the decade with excellent
result in treatment of various clinical indications, but the market
remains widely untapped due to the high price tag.
The cell therapy technique finds wide usage in almost all types of
therapeutic areas. However, the majority of the cell therapy research is
currently being done in cancer, Neurological, Cardiovascular and
Inflammatory segments due to their high mortality rate among the global
population. Few cell therapy research is being done in the diabetic
segment too where the aim is to develop an artificial pancreas using
cell therapy which would work just like a natural pancreas.
Cell therapies will also have the potential to replace many risky,
costly and invasive surgeries. For many disease conditions, such as
diabetes, patients are required to take a prescription on a daily basis.
A cell therapy approach will substantially reduce the healthcare costs
of this disease by providing a one-time treatment. In the same way cell
therapy approaches to pain management will also reduce the costs of
opioid-based pain medications. Cell therapy, in combination with the
recent advances in iPS cell generation and CRISPR-Cas 9, also has a
great opportunity in the future.
The path towards the success for cell therapy will consist of a
combination of scenarios that is being imagined for the cure of diseases
and is hoped that these will definitely come true in the near future.
The advantages and risks of current cell therapy practices will improve
translational success and accelerate the clinical development of safe
and efficient cell products in the future.
Key Topics Covered:
1. Overview of Cell Therapy
1.1 Introduction to Cell Therapy
1.2 History & Evolution of Cell Therapy
2. Types of Cell Therapy
2.1 Allogeneic Cell Therapy
2.2 Autologous Cell Therapy
2.3 Human Embryonic Stem Cell Therapy
2.4 Neural Stem Cell Therapy
2.5 Mesenchymal Stem Cell Therapy
2.6 Hematopoietic Stem Cell Transplantation
3. Mechanism of Therapeutic Action in Cell Therapy
4. Manufacturing of Cell Therapies
4.1 Models for Manufacturing Cell Therapies
4.2 Facilities for Good Manufacturing Practice
5. Advantages of Cell Therapy Over Conventional Therapy
5.1 Anti-Aging with Cell Therapy
5.2 Addressing Other Diseases with Cell Therapy
6. Personalized Cell Therapy
6.1 Overview of Personalized Cell Therapy
6.2 Personalized Cell Therapy Using Epigenetic Tools
6.3 Personalized Cell Therapy through Mesenchymal Stem Cells
6.4 Treatment of Parkinson’s Disease through IPSCs
6.5 Case Study: Personalized Cell Therapy for Pulpitis Using Autologous
Dental Pulp Stem Cells & Leukocyte Platelet Rich Fibrin
7. Cell Therapy Application by Therapeutic Areas
7.1 Cardiovascular Disease
7.2 Neurological Disorders
7.3 Inflammatory Diseases
7.4 Diabetes
7.5 Cancer
8. Global Cell Therapy Market Outlook
8.1 Current Market Scenario
8.2 Cell Therapy Market by Cell Source
8.2.1 Induced Pluripotent Stem Cell (IPSCs)
8.2.2 Bone Marrow
8.2.3 Umbilical Cord Blood Derived Cells
8.3 Global Cell Therapy Clinical Pipeline (Company,Indication, Region)
Overview
9. US – Cell Therapy Dosage & Cost Analysis
9.1 Allocord
9.2 Laviv
9.3 Maci
9.4 Clevecord
9.5 Hemacord
9.6 Ducord
9.7 Provenge
9.8 HPC, Cord Blood (Clinimmune Labs, University of Colorado Cord Blood
Bank)
9.9 HPC, Cord Blood (LifeSouth Community Blood Centers, Inc)
9.10 HPC, Cord Blood (Bloodworks)
9.11 HPC, Cord Blood (MD Anderson Cord Blood Bank)
9.12 Gintuit
9.13 Kymriah*
9.14 Yescarta*
9.15 Carticel
10. South Korea – Cell Therapy Dosage & Cost Analysis
10.1 Cartistem
10.2 Chondron
10.3 KeraHeal
10.4 Cellgram
10.5 Cure Skin Injection
11. Australia, Europe & Japan – Cell Therapy Dosage & Cost
Analysis
11.1 Holoclar (Europe)
11.2 Yescarta (EU)
11.3 Kymriah (EU)
11.4 Temcell HS (Japan)
11.5 Chondrocytes-T-Ortho-ACI (Australia)
12. Cell Therapy Market Trends: Geographically
12.1 US
12.2 South Korea
12.3 Europe
12.4 Japan
12.5 China
12.6 Rest of the World
12.6.1 Africa
12.6.2 Middle East
12.6.3 South America
13. Advancements in Cell Therapy
13.1 Drug Based Therapies Advancements in Chronic Lymphocytic Leukemia
13.2 Advances in Cytomegalovirus Infection Prevention & Treatment
13.3 Stem Cell Therapy for the Treatment of Parkinson’s Disease
13.4 Stem Cell Therapy for the Treatment of Alzheimer’s Disease
13.5 Treatment of Rheumatoid Arthritis via Stem Cell Therapy
13.6 Role of Stem Cell Therapy in Treating Infertility
13.7 Stem Cells for Eye Diseases
13.8 Cell Therapy for Stroke and Angina Pectoris
13.9 Stem Cell Therapy in Improving Wrinkles & Acne Scars
14. Treg Cells – The Next Edge of Cell Therapy
14.1 Introduction to Treg Cell
14.2 Isolation & Expansion of Treg Cell
14.3 Mechanism of Action
14.4 Clinical Trials of Treg Cell Therapy
14.4.1 Adoptive Cell Therapy of Treg cells to Prevent GvHD
14.4.2 Adoptive Cell Therapy of Polyclonal & Alloantigen-specific Treg
cells to Prevent Solid Organ Transplant Rejection
14.5 Treg Cell Therapy for the Treatment of Autoinflammatory &
Autoimmune Diseases
14.5.1 Inflammatory Bowel Disease
14.5.2 Systemic Lupus Erythematosus
14.5.3 Autoimmune Hepatitis
14.5.4 Pemphigus Vulgaris
14.5.5 Allergy and Asthma
14.6 Future Prospects of Treg Cell Therapy
15. Global Cell Therapy Market Dynamics
15.1 Market Drivers
15.2 Commercial Challenges
16. Global Cell Therapy Market Future Prospects
17. Marketed Cell Therapies Clinical Insight by Company &
Indication
17.1 Tisagenlecleucel (Kymriah)
17.2 Axicabtagene Ciloleucel (Yescarta)
17.3 Allogeneic Cultured Keratinocytes And Fibroblasts (Gintuit)
17.4 Adipose Stem Cell Therapy (Adipocell (Anterogen), Cupistem &
Queencell)
17.5 Tonogenchoncel-L (INVOSSA-K inj)
17.6 Mesenchymal Stem Cell Therapies (Stempeucel)
17.7 Remestemcel-L (Prochymal & TEMCELL HS Inj.)
17.8 Sipuleucel-T (Provenge)
17.9 Autologous Mesenchymal Stem Cell Therapy – Pharmicell
17.10 Autologous Cultured Chondrocytes (MACI)
17.11 Autologous Cultured Chondrocytes (Chondrotransplant DISC)
17.12 Autologous Corneal Epithelial Stem Cell Therapy (Holoclar)
17.13 Nalotimagene Carmaleucel (Zalmoxis)
17.14 Mesenchymal Stem Cell Therapy For Cartilage Repair (Cartistem)
17.15 Autologous Chondrocyte Implant – TETEC
17.16 Muscle-Derived Autologous Stem Cell Therapy (MyoCell)
17.17 Human Skin Replacement (CellSpray)
17.18 Leukocyte Cell Therapy (CureXcell)
17.19 Autologous Cultured Chondrocyte Implant (Carticel)
17.20 Azficel-T (Laviv)
17.21 Autologous Cultured Chondrocytes (CHONDRON)
17.22 Autologous Chondrocytes (BioCart)
17.23 Amniotic Cell Therapy (NuCel)
17.24 Dendritic Cell-Activated Cytokine-Induced Killer Cells – Shanghai
Jia Fu Medical
17.25 Autologous Cultured Myoblasts And Fibroblasts (Urocell)
18. Global Cell Therapy Clinical Pipeline by Company, Indication
& Phase
18.1 Research
18.2 Preclinical
18.3 Clinical
18.4 Phase-0
18.5 Phase-I
18.6 Phase-I/II
18.7 Phase-II
18.8 Phase-II/III
18.9 Phase-III
18.10 Preregistration
18.11 Registered
19. Competitive Landscape
19.1 Athersys Inc.
19.2 Baxter Healthcare Corporation
19.3 Bone Therapeutics
19.4 Celgene Corporation
19.5 Cell Medica
19.6 Cellerant Therapeutics
19.7 FibrocellScinence
19.8 Genzyme Corporation
19.9 Green Cross Cell
19.10 Histogenics Corporation
19.11 Intrexon Corporation
19.12 Intercytex
19.13 ISTO Biologics
19.14 Macrocure
19.15 Mesoblast
19.16 Molmed
19.17 Nuo Therapeutics Inc
19.18 OmniCyte
19.19 Opexa Therapeutics
19.20 Organogenesis
19.21 Pharmicell
19.22 TCA Cellular Therapy
19.23 Stem Cell Inc.
19.24 Teva Pharmaceuticals
19.25 Tigenix
19.26 Vericel Corporation
For more information about this report visit https://www.researchandmarkets.com/r/d51vww
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Genomics,
Clinical
Trials